Browsing: eVOLVELung02

Diagnosis

eVOLVE-Lung02 Trial of Volrustomig Discontinued in Metastatic NSCLC

By NewsCancerAugust 17, 20260

AstraZeneca is discontinuing the phase 3 eVOLVE-Lung02 trial (NCT05984277), which evaluated volrustomig plus chemotherapy vs pembrolizumab (Keytruda) plus chemotherapy as…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Where Will Cell and Gene Therapy Go Next in Multiple Myeloma?

eVOLVE-Lung02 Trial of Volrustomig Discontinued in Metastatic NSCLC

A targetable ALDH3A2-NRF2 axis mediates KEAP1-mutant tumour development via ferroptosis inhibition

Browsing: eVOLVELung02

eVOLVE-Lung02 Trial of Volrustomig Discontinued in Metastatic NSCLC

Where Will Cell and Gene Therapy Go Next in Multiple Myeloma?

eVOLVE-Lung02 Trial of Volrustomig Discontinued in Metastatic NSCLC

A targetable ALDH3A2-NRF2 axis mediates KEAP1-mutant tumour development via ferroptosis inhibition

Chemoimmunotherapy Combo Exhibits Deep Pathologic Response in HNSCC

Where Will Cell and Gene Therapy Go Next in Multiple Myeloma?

eVOLVE-Lung02 Trial of Volrustomig Discontinued in Metastatic NSCLC

A targetable ALDH3A2-NRF2 axis mediates KEAP1-mutant tumour development via ferroptosis inhibition

Chemoimmunotherapy Combo Exhibits Deep Pathologic Response in HNSCC

Latest Post

Where Will Cell and Gene Therapy Go Next in Multiple Myeloma?

eVOLVE-Lung02 Trial of Volrustomig Discontinued in Metastatic NSCLC

A targetable ALDH3A2-NRF2 axis mediates KEAP1-mutant tumour development via ferroptosis inhibition

Subscribe to Updates

What's Hot

Browsing: eVOLVELung02